Inter-tumor heterogeneity

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 8, 2012, Pages 1143-1145

  Cusnir, Mike ^a   Cavalcante, Ludmila ^a  

^a Mount Sinai Comprehensive Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CLINICAL PRACTICE; ENZYME ACTIVITY; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HIGH RISK PATIENT; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NOTE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION;

GENETIC VARIATION; HUMANS; NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84866131656     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.21203     Document Type: Note

References (8)

1. Ichikawa W, Takahashi T, Suto K, Yamashita T, Nihei Z, Shirota Y, et al. Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 2004; 91:1245-50; PMID:15354215; http://dx.doi.org/10.1038/sj.bjc.6602139.
2. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349:247-57; PMID:12867608; http://dx.doi.org/10.1056/NEJMoa022289.
3. Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011; 29:1261-70; PMID:21383284; http://dx.doi.org/10.1200/JCO.2010.30.1366.
4. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-34; PMID:18316791; http://dx.doi.org/10.1200/JCO.2007.14.7116.
5. European consortium data. Lancet Oncol 2010; 11:753-62; PMID:20619739.
6. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009; 27:2622-9; PMID:19398573; http://dx.doi.org/10.1200/JCO.2008.20.2796.
7. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009; 101:1308-24; PMID:19738166; http://dx.doi.org/10.1093/jnci/djp280.
8. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318:1108-13; PMID:17932254; http://dx.doi.org/10.1126/science.1145720.